Enzon Pharmaceuticals Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Date: December 1, 2016
Pages: 50
Price:
US$ 499.00
Enzon Pharmaceuticals Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Publisher: BAC Reports
Report type: Strategic Report
Delivery: E-mail Delivery - PDF (on default),
Hard Copy Mail Delivery (+US$ 190.00)
ID: EDE798AD65EBEN
Leaflet:

Download PDF Leaflet

Enzon Pharmaceuticals Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Enzon Pharmaceuticals Inc. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Enzon Pharmaceuticals Inc. and its competitors. This provides our Clients with a clear understanding of Enzon Pharmaceuticals Inc. position in the Pharmaceuticals and Biotechnology Industry.

  • The report contains detailed information about Enzon Pharmaceuticals Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
  • Another part of the report is a SWOT-analysis carried out for Enzon Pharmaceuticals Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
  • The Enzon Pharmaceuticals Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
  • In the part that describes Enzon Pharmaceuticals Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
  • Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Enzon Pharmaceuticals Inc. business.

About Enzon Pharmaceuticals Inc.

Enzon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of important medicines for patients with cancer.

Technologies and Products

The company’s drug development program utilizes various technologies, including its customized linker technology and the locked nucleic acid (LNA) technology. The company has three compounds in human clinical development: PEG-SN38, the HIF-1 alpha antagonist, and the Survivin antagonist. It has a license and collaboration agreement with Santaris for approximately eight mRNA antagonists which it intends to develop. The company holds rights worldwide, other than Europe, to develop and commercialize mRNA antagonists based on LNA technology directed against the HIF-1 alpha and Survivin mRNA targets.

PEG-SN38

The company’s PEG-SN38 compound utilizes its PEGylation technology together with SN38, which is the active metabolite of the cancer drug, irinotecan. PEG-SN38 is designed to allow for intravenous delivery, increased solubility, higher exposure of the cancer cells to SN38, and longer apparent half-life. The company has completed Phase I trials and is enrolling patients in two Phase II clinical trials with PEG-SN38 in patients with metastatic colorectal and breast cancer, as well as a Phase I trial for pediatric patients with cancer. The company has licensed various RNA antagonists directed against oncology targets.

LNA Technology-Based Programs

HIF-1 Alpha Antagonist: The company’s first antagonist to enter the clinic is the hypoxia-inducible factor 1 alpha (HIF-1 alpha) target. HIF-1 alpha is a validated target in various cancer types, including solid tumors. The company is conducting two Phase I studies with HIF-1 alpha in patients with solid tumors and lymphoma to evaluate different dosing schedules.

Survivin Antagonist: The company’s second antagonist is Survivin. Survivin is heavily over-expressed in various cancers and in newly formed endothelial cells engaged in angiogenesis. The company is enrolling patients in a Phase I study for patients with solid tumors and lymphoma.

Six Additional Gene Targets

The company also has rights to six additional mRNA targets that are being evaluated in early preclinical studies.

Royalties

The company also licenses its PEGylation platform for various products, such as PEGINTRON (peginterferon alfa-2b), which is marketed by Merck Corporation; Macugen (pegaptanib sodium injection), which is marketed by OSI Pharmaceuticals, Inc. and Pfizer Inc.; and CIMZIA (certolizumab pegol), which is marketed by UCB Pharma.

The company has out-licensed its proprietary PEGylation and single-chain antibody (SCA) technologies on its own and through agreements with Nektar Therapeutics, Inc. (Nektar) and Micromet AG (Micromet).

Dispositions

In January 2010, the company sold its specialty pharmaceutical business, consisting principally of its products segment and contract manufacturing segment.

Competition

Technology

PEGylation: The company's competitors include The Dow Chemical Company; Nektar Pharmaceuticals, Inc.; SunBio Corporation; Mountain View Pharmaceuticals, Inc.; Neose Technologies, Inc.; NOF Corporation; and Urigen Pharmaceuticals, Inc.

Locked Nucleic Acid: The company's competitors include Isis Pharmaceuticals, Inc.; Alnylam Pharmaceuticals, Inc.; Regulus Therapeutics LLC; and Eli Lilly and Company.

Product Candidates: The company's competitors include Bristol-Myers Squibb Company; Pfizer Inc.; GlaxoSmithKline plc; Antigenics Inc.; F. Hoffman-La Roche Ltd.; Novartis AG; Cell Therapeutics, Inc.; Neopharm, Inc.; Meditech Research Limited; Nektar Therapeutics; Isis Pharmaceuticals/Eli Lilly; Astellas; Erimos; and Aegera.

Royalties

PEGINTRON: PEGINTRON, marketed by Merck, competes directly with Hoffmann-La Roche’s Pegasys.

Macugen: Macugen, marketed by OSI Pharmaceuticals, Inc. and Pfizer Inc., competes with products developed by QLT, Inc.; Novartis AG; and Genetech.

History

Enzon Pharmaceuticals, Inc. was founded in 1981.


The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

RESEARCH METHODOLOGY

DISCLAIMER

1. ENZON PHARMACEUTICALS INC. COMPANY PROFILE

1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History

2. ENZON PHARMACEUTICALS INC. BUSINESS OVERVIEW

2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units

3. ENZON PHARMACEUTICALS INC. SWOT ANALYSIS

3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats

4. ENZON PHARMACEUTICALS INC. FINANCIAL ANALYSIS

4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot

5. ENZON PHARMACEUTICALS INC. COMPETITORS AND INDUSTRY ANALYSIS

5.1. Enzon Pharmaceuticals Inc. Direct Competitors
5.2. Comparison of Enzon Pharmaceuticals Inc. and Direct Competitors Financial Ratios
5.3. Comparison of Enzon Pharmaceuticals Inc. and Direct Competitors Stock Charts
5.4. Enzon Pharmaceuticals Inc. Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Enzon Pharmaceuticals Inc. Industry Position Analysis

6. ENZON PHARMACEUTICALS INC. NEWS & EVENTS

6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events

7. ENZON PHARMACEUTICALS INC. EXPERTS REVIEW1

7.1. Experts Opinion
7.2. Experts Estimates

8. ENZON PHARMACEUTICALS INC. ENHANCED SWOT ANALYSIS2

9. UNITED STATES PESTEL ANALYSIS2

9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors

10. ENZON PHARMACEUTICALS INC. IFE, EFE, IE MATRICES2

10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix

11. ENZON PHARMACEUTICALS INC. PORTER FIVE FORCES ANALYSIS2

12. ENZON PHARMACEUTICALS INC. VRIO ANALYSIS2


APPENDIX: RATIO DEFINITIONS


LIST OF TABLES

Enzon Pharmaceuticals Inc. Key Facts
Profitability
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Enzon Pharmaceuticals Inc. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Enzon Pharmaceuticals Inc. Major Shareholders
Enzon Pharmaceuticals Inc. History
Enzon Pharmaceuticals Inc. Products
Revenues by Segment
Revenues by Region
Enzon Pharmaceuticals Inc. Offices and Representations
Enzon Pharmaceuticals Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Enzon Pharmaceuticals Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Enzon Pharmaceuticals Inc. Capital Market Snapshot
Enzon Pharmaceuticals Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Enzon Pharmaceuticals Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Enzon Pharmaceuticals Inc. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Historical Surprises1
Revenue Estimates Trend1
Earnings Estimates Trend1
Revenue Revisions1

LIST OF FIGURES

Enzon Pharmaceuticals Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Enzon Pharmaceuticals Inc. 1-year Stock Charts
Enzon Pharmaceuticals Inc. 5-year Stock Charts
Enzon Pharmaceuticals Inc. vs. Main Indexes 1-year Stock Chart
Enzon Pharmaceuticals Inc. vs. Direct Competitors 1-year Stock Charts
Enzon Pharmaceuticals Inc. Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

  • How to use the strengths to take advantage of the opportunities?
  • How to use the strengths to reduce likelihood and impact of the threats?
  • How to overcome the weaknesses that obstruct taking advantage of the opportunities?
  • How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.


PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

  • Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
  • Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
  • Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
  • Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
  • Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
  • Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.


Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

  1. What composes a threat of substitute products and services?
  2. Is there a threat of new competitors entering the market?
  3. What is the intensity of competitive rivalry?
  4. How big is the bargaining power of buyers?
  5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

  • Tangible resources
    • Financial
    • Physical
    • Technological
    • Organizational
  • Intangible resources
    • Human
    • Innovation and Creativity
    • Reputation
  • Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

  • Valuable?
  • Rare?
  • Costly to imitate?
  • Organized properly?
Skip to top


Ask Your Question

Enzon Pharmaceuticals Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: